Clinical Trial Update: Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and immune response of an investigational vaccine for Respiratory syncytial virus infection and Human metapneumovirus infect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Investigational RSV/hMPV vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: RSV Infection, hMPV | Phase 1 | Status: COMPLETED